Thursday, December 31, 2015

Genetic Testing 101


By Guest Blogger: Troy Moore, Chief Scientific Officer, Kailos Genetics


Examining genetics for clues to cancer risk

Genetic testing offers new hope to those with a family history of cancer, helping to establish risk levels and pinpointing the best course of treatment for certain cancers.

Yet for all of its benefits, genetic testing is still in its infancy. It’s only been 25 years since the Human Genome Project was launched, and the secrets of human DNA are still being unlocked.

The benefits of genetic testing
Virtually everyone can benefit from knowing more about their DNA, especially if there’s a family history of cancer. You may have inherited more than your father’s unibrow and
Aunt Agnes’s china collection – there may also be a higher risk for cancer.

Because family history is a primary indicator of risk, you should be aware of who in your family had cancer and what types. Without genetic screening, it’s difficult to know if you are in a high-risk category and should start early screenings.


The genetic testing process
Genetic testing has become much simpler than in the past. Not only is it more affordable, but some labs can process a test based upon a simple cheek swab. The exception is if you are testing a tumor – a sample of the tumor will be needed to evaluate those genetic cells.

Almost any type of cancer has a set of DNA changes associated with it. Usually people are tested for specific types of cancer based upon their family history or environmental factors that may contribute to cancer (such as smoking).

Working with a genetic counselor before you are tested can help you determine which tests would be most useful. If your family history doesn’t indicate testing for certain types of cancer, you might consider testing for the most common types of cancer – breast, prostate, lung and colon. There is a strong knowledge base around those cancers, and the tests are well proven. The information the tests provide can be used to set an appropriate screening schedule based on risk.

Once tested, your genetic counselor can also help you interpret the results; for example, the counselor could explain that even though you have twice the risk of the general population for a type of cancer, if the occurrence is very low you probably don’t need to worry. They can also help to provide advice on how to discuss your testing with your family. Because you share the same genes, your genetic test can have implications for other members of the family.

Deciphering variants of unknown significance
The human genome has been mapped, but there is still much to learn about genetic changes, or mutations. After all, there are over three billion base pairs in the genome. Imagine the genome map as a road map that shows major highways and roads but doesn’t include smaller streets. As people travel those unmapped streets and information is gathered, the road map becomes more informative and useful.

This lack of information can be frustrating for people who have variants of unknown significance (VUS). While occasionally the VUS may be totally unique, frequently there just isn’t sufficient clinical data associated with it to know how it affects your risk of developing cancer.

Having a VUS doesn’t necessarily put you into a high-risk category; however, it does mean that a physician won’t be able to use that part of your genetic information to recommend earlier screenings or adjust a course of treatment. However, it is important that this information is cataloged into a public database, so that new insights about each VUS can be shared.

In the past, there was only one company conducting genetic testing and they kept the data they obtained proprietary. However, the National Institute of Health (NIH) has established and maintains a repository where clinical researchers and testing laboratories can deposit information about DNA changes and the criteria they used to make an assessment.

As more patient information is aggregated around a particular VUS, its meaning will become clearer. That’s why growing the NIH database benefits everyone – and helps add information around those gaps in the genome map.

Genetic testing is yielding new insights and understands of the role genes play in cancer risk and treatments. With the growth of this knowledge base, it will become increasingly valuable in the future.

Sunday, December 6, 2015

"Information is Power" - Population Screening (Part 1)



Autosomal dominant mutations, like BRCA1 and BRCA2 are inherited at equal rates from mothers and fathers. However, the cancer risks differ between men and women. Currently genetic testing is only recommended to those who have cancer or those who have a strong family history of cancer. Within the high risk, research, and clinical communities there has been a lot of discussion about “population screening” in regards to cancer genetics. Dr. Mary-Claire King (credited with the discovery of BRCA1) has publicly advocated for population screening, recommending all women be offered genetic testing at age 30, regardless of family history.

Population screening is not a new concept, in fact it is often recommended for early detection of cancer. The USPSTF (U.S. Preventive Services Task Force) recommends women get a mammogram every 1-2 years, beginning at age 50. The American Cancer Society recommends mammograms annually beginning at age 45.

Dr. King and Ephrat Levy-Lahad, MD (Director of the Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel) led a study in 2014 to determine how the breast and ovarian cancer risk among BRCA1/BRCA2 carriers in the general population compared with that among carriers with a history of breast or ovarian cancer. 

The authors write, "In this study, 51% (85 of 167) families harboring BRCA1 or BRCA2 mutations had little or no history of relevant cancer. These families were small and included few females with mutations who had reached the ages of highest cancer risk. Young women in these families would not have been tested in the absence of a general screening program."

In 2014, Dr. Mary-Claire King challenged Huntsville/Madison County (Alabama) to be the first community to offer free genetic testing to 30-year-old women, regardless of family history. Kailos Genetics, in partnership with HudsonAlpha Institute for Biotechnology, accepted this challenge through a genetic testing program, “Information is Power”. The first free test kits were given out at the 2015 Tie the Ribbons event on October 29, 2015. Free/discounted tests will be available through the Kailos website for one full year, until October 29, 2016 for anyone over the age of 19 who lives in Madison, Jackson, Limestone, Marshall and Morgan counties (Alabama).

To date, Kailos has had over 500 participants take advantage of free or discounted genetic testing. We look forward to seeing what the results of this pilot population screening reveal.